The North America veterinary clinical trials market size is expected to reach USD 3,841.20 million by 2032, exhibiting a compound annual growth rate (CAGR) of 10.0% during the forecast period (2024 – 2032).
The North America veterinary clinical trials market is a pivotal segment within the animal healthcare sector, encompassing the development and testing of new drugs, vaccines, and therapeutic solutions for animals. The region’s established pharmaceutical infrastructure, rising pet ownership, and growing emphasis on livestock productivity make it a leader in veterinary clinical trials.
Market Growth Drivers
- Rising Prevalence of Animal Diseases
- Increasing cases of zoonotic and infectious diseases, such as rabies and bovine respiratory disease, drive the need for effective treatments and vaccines.
- Surging Pet Ownership and Spending
- North America has one of the highest rates of pet ownership globally, with significant spending on pet health, creating demand for innovative treatments and clinical trials.
- Growth in Livestock Production
- The demand for animal-derived food products necessitates trials for vaccines and therapeutics to ensure livestock health and productivity.
Download Free Sample PDF Copy of the Report:
Key Companies in the North America Veterinary Clinical Trials market include
- Argenta
- Boehringer Ingelheim International GmbH
- Cambridge Technologies
- Charles River Laboratory
- Clinvet
- IDEXX Laboratories, Inc.
- Knoell
- Labcorp Drug Development
Key Market Trends
- Precision Medicine in Veterinary Care
- Advances in genomics and diagnostics are enabling tailored treatments for specific animal breeds and conditions.
- Digital Tools Integration
- Wearable devices, telemedicine platforms, and AI-driven analytics are increasingly used in trials to monitor animal health and collect data.
- One Health Approach
- Collaborative efforts between veterinary and human healthcare sectors to address zoonotic diseases, aligning with global health priorities.
𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰:
The research report categorizes the market into various segments and sub-segments. The primary segments covered in the study include type, application, end use and region. The splitting of the market into various groups enables businesses to understand market preferences and trends better. Also, stakeholders can develop products/services that align with the diverse needs of consumers in the industry. Besides, the research study includes a thorough examination of all the major sub-segments in the market.
North America Veterinary Clinical Trials Animal Type Outlook
- Livestock Animal
- Companion Animal
- Other Animals
North America Veterinary Clinical Trials Intervention Outlook
- Medicines
- Medical Device
- Others
North America Veterinary Clinical Trials, Indication Outlook
- Orthopedics
- Oncology
- Cardiology
- Ophthalmology
- Neurology
- Dermatology
- Internal Medicine
- Other Indication
North America Veterinary Clinical Trials End User Outlook
- Academics And Research Centers
- Pharmaceutical And Biopharmaceutical Companies
- Others
North America Veterinary Clinical Trials Industry Developments
- April 2024: April 2024: Zoetis announced the U.S. launch of Bonqat (pregabalin oral solution) for cats under an exclusive agreement with Orion Corporation. The FDA approved these Bonqat in November 2023 to help alleviate feline anxiety and fear related to transportation and veterinary visits.
- March 2024: Vivesto AB announced that it has started its Paccal Vet clinical trial by giving the first dose to a dog with splenic hemangiosarcoma after spleen removal surgery.
- April 2022: Charles River Laboratories International, Inc. acquired Explora BioLabs Holdings, Inc., to broaden Charles River’s Accelerator and Development Lab (CRADL), a part of its Insourcing Solutions business which offers fully equipped, AAALAC-accredited vivarium rental spaces, supported by Charles River’s extensive technical, vivarium, and veterinary capabilities.
North America Veterinary Clinical Trials Market: An Overview
The North America veterinary clinical trials market is a pivotal segment within the animal healthcare sector, encompassing the development and testing of new drugs, vaccines, and therapeutic solutions for animals. The region’s established pharmaceutical infrastructure, rising pet ownership, and growing emphasis on livestock productivity make it a leader in veterinary clinical trials.
In 2023, the North America veterinary clinical trials market was valued at approximately $510 million and is projected to grow at a CAGR of 8.2% from 2023 to 2030. This growth is fueled by advancements in veterinary medicine, increasing demand for innovative animal healthcare solutions, and a robust regulatory framework.
Market Overview
Veterinary clinical trials in North America play a crucial role in the approval of animal healthcare products, ensuring safety and efficacy for both companion and livestock animals. The market is characterized by:
- A strong focus on companion animal trials, driven by rising pet ownership and expenditure on pet health.
- Livestock trials targeting productivity and disease prevention, especially for cattle, poultry, and swine.
- Stringent regulatory oversight, led by the U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM) and the Canadian Food Inspection Agency (CFIA).
Market Growth Drivers
- Rising Prevalence of Animal Diseases
- Increasing cases of zoonotic and infectious diseases, such as rabies and bovine respiratory disease, drive the need for effective treatments and vaccines.
- Surging Pet Ownership and Spending
- North America has one of the highest rates of pet ownership globally, with significant spending on pet health, creating demand for innovative treatments and clinical trials.
- Growth in Livestock Production
- The demand for animal-derived food products necessitates trials for vaccines and therapeutics to ensure livestock health and productivity.
- Regulatory Support
- The FDA CVM mandates comprehensive clinical trials for veterinary products, ensuring high standards and driving market activity.
- Technological Advancements in Veterinary Medicine
- Innovations in biologics, gene therapy, and precision medicine are expanding the scope of veterinary clinical trials.
Key Market Trends
- Precision Medicine in Veterinary Care
- Advances in genomics and diagnostics are enabling tailored treatments for specific animal breeds and conditions.
- Digital Tools Integration
- Wearable devices, telemedicine platforms, and AI-driven analytics are increasingly used in trials to monitor animal health and collect data.
- One Health Approach
- Collaborative efforts between veterinary and human healthcare sectors to address zoonotic diseases, aligning with global health priorities.
- Expansion of Companion Animal Trials
- Trials for chronic conditions like arthritis, cancer, and diabetes in pets are on the rise due to increasing demand for advanced therapies.
- Rise of Contract Research Organizations (CROs)
- The presence of specialized veterinary CROs in North America facilitates cost-effective and efficient trial management.
Market Segmentation
- By Study Design
- Interventional Trials: Focused on testing new drugs, vaccines, and treatment protocols.
- Observational Studies: Evaluating natural disease progression and treatment outcomes without intervention.
- By Animal Type
- Companion Animals:
- Dogs
- Cats
- Horses
- Livestock Animals:
- Cattle
- Poultry
- Swine
- By Indication
- Chronic Diseases
- Cancer, arthritis, diabetes.
- Infectious Diseases
- Rabies, avian flu, swine fever.
- Zoonotic Diseases
- Brucellosis, leptospirosis.
- By End-User
- Veterinary Hospitals and Clinics
- Pharmaceutical and Biopharmaceutical Companies
- Academic and Research Institutions
- Contract Research Organizations (CROs)
- By Country
- United States:
- The largest market, driven by advanced veterinary infrastructure, high pet ownership, and regulatory rigor.
- Canada:
- Emerging market with growing investments in animal health research and livestock productivity.
Challenges in the Market
- High Costs of Veterinary Clinical Trials
- The need for specialized facilities, skilled personnel, and compliance with regulatory standards increases trial expenses.
- Ethical Concerns
- Growing scrutiny over the use of animals in research necessitates adherence to strict ethical guidelines, adding complexity to trial designs.
- Regulatory Complexity
- While the FDA CVM provides clear guidelines, navigating multi-country regulatory requirements can be challenging.
- Limited Availability of Participants
- Recruiting adequate animal participants, especially for rare conditions, remains a bottleneck.
- Competition from Generic Products
- The rise of generic veterinary drugs may reduce incentives for conducting extensive clinical trials.
Research Scope
Future research in the North America veterinary clinical trials market includes:
- Development of Innovative Vaccines
- For emerging diseases like African Swine Fever and zoonotic infections.
- Advancement in Biologics and Gene Therapies
- Targeting chronic and complex diseases in companion animals.
- Technological Integration
- Incorporating AI, machine learning, and IoT devices to improve trial accuracy and efficiency.
- Focus on Alternative Testing Models
- Developing non-animal models such as organ-on-chip technologies to reduce animal use in trials.
Conclusion
The North America veterinary clinical trials market is positioned for robust growth, driven by rising demand for advanced animal healthcare solutions, increasing pet ownership, and a strong regulatory framework. While challenges like high costs and ethical concerns persist, advancements in precision medicine, digital tools, and livestock management offer significant opportunities for market expansion.